The European regulatory body’s February 2025 meeting brings fresh treatment options for immunodeficiency and autoimmunity among other conditions, …
The European regulatory body’s February 2025 meeting brings fresh treatment options for immunodeficiency and autoimmunity among other conditions, …
February 2025 sees a surge in large-scale biotech investments—from Eikon’s massive Series D to critical autoimmune and oncology …
Innovation, investment, and ideals intersected dramatically at the AI Action Summit—held 10–11 February at Paris’s Grand Palais. Co-chaired …
The 26th Clinical Trial Supply Europe conference (25–26 February, Barcelona) will showcase how AI, logistics innovation, and regulatory …
Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
On February 1, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s lebrikizumab, marking the first …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Already a subscriber? Log in